The provision of a patent system that protects innovators and researchers while ensuring reasonable access to emerging technologies and medical treatments are the key objectives of the Australian government's response to three important reports concerning Australia's patent system and gene patents.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Kirin-Amgen Inc v Board of Regents of University of Washington (1995) 33 IPR 557.
Genetics Institute Inc v Kirin-Amgen Inc (1996) 34 IPR 513.
Senate Committees inquiry on the Patent Amendment (Human Genes and Biological Materials) Bill 2010. Submissions received by the Committee. http://www.aph.gov.au/Parliamentary_Business/Committees/Senate_Committees?url=legcon_ctte/patent_amendment/submissions.htm
Australian Law Reform Commission. ALRC Submission to Senate Standing Committee on Community Affairs Inquiry into Gene Patents (ALRC, 18 March 2009). http://www.alrc.gov.au/senate-standing-committee-community-affairs-inquiry-gene-patents
Australian Law Reform Commission. Advisory Council on Intellectual Property Review of Patentable Subject Matter (ALRC, December 2010). http://www.acip.gov.au/library/ACIP%20PSM%20final%20report%204%20Feb%202011.pdf
Australian Law Reform Commission. Genes and Ingenuity: Gene Patenting and Human Health (ALRC, 30 August 2004). http://www.alrc.gov.au/publications/report-99
Anonymous. Australian Government Response to Senate Community Affairs References Committee Gene Patents Report (23 November 2011) http://www.ipaustralia.gov.au/46106/Australian_Government_Response_to_Senate_Committee_Gene_Patents_Report.pdf
Cancer Voices Australia & Anor v Myriad Genetics Inc & Ors, Federal Court of Australia, NSD643 (2010).
Myriad Genetics, Inc. In vivo mutations and polymorphisms in the 17q-linked breast and ovarian cancer susceptibility gene. Australian patent no. 686004 (1995). http://pericles.ipaustralia.gov.au/ols/auspat/applicationDetails.do?applicationNo=1995033212
http://www.cafc.uscourts.gov/images/stories/opinions-orders/10-1406.pdf
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Simmons, D., Wickham, M. Gene patents in Australia: where do we stand?. Nat Biotechnol 30, 323–324 (2012). https://doi.org/10.1038/nbt.2173
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.2173
This article is cited by
-
D’Arcy v. Myriad Genetics: A Demand for the “Made” or “Non-Information” and Clear Subject Matter?
IIC - International Review of Intellectual Property and Competition Law (2016)